Form 4: Coherus Oncology Director Ali J. Satvat Granted 112,000 Stock Options

Coherus Oncology, Inc. Director Ali J. Satvat was granted 112,000 stock options with an exercise price of $0.7904, vesting fully on June 11, 2026.

Summary

• Ali J. Satvat, a Director of Coherus Oncology, Inc. (CHRS), was granted 112,000 stock options.
• The transaction date for this grant was June 12, 2025.
• Each stock option has an exercise price of $0.7904.
• The options are for the right to buy Common Stock of Coherus Oncology, Inc.
• The entire grant of 112,000 options will vest and become exercisable on the one-year anniversary of June 11, 2025, which is June 11, 2026.
• Vesting is contingent upon Mr. Satvat's continued service relationship with the Issuer.
• The stock options have an expiration date of June 12, 2035.
• Following this transaction, Mr. Satvat beneficially owns 112,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive step for aligning management incentives with shareholder interests, though it is a routine compensation event rather than a significant operational or financial announcement that would drastically alter the company's outlook.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• The options provide a potential future value for the director, contingent on the company's stock price appreciation above the exercise price.

Negatives

• The options do not provide immediate liquidity or cash flow to the director.
• The value of the options is dependent on future stock price performance, introducing market risk.
• The vesting schedule requires continued service, meaning the options could be forfeited if the director's service relationship with the company ends before the vesting date.

Risks

• Market risk: The value of the stock options is directly tied to the future market price of Coherus Oncology's common stock. If the stock price does not rise above the exercise price of $0.7904, the options may expire worthless.
• Forfeiture risk: The options are subject to a vesting schedule, and if the reporting person's service relationship with the Issuer ceases before the vesting date (June 11, 2026), the unvested options may be forfeited.

Future Outlook

The stock option grant serves as an incentive for the director's continued service and aligns their future financial interests with the long-term performance and value creation of Coherus Oncology, Inc.

Management Comments

• The grant of stock options to Director Ali J. Satvat reflects the company's strategy to incentivize key personnel and align their interests with shareholder value creation through equity-based compensation.

Industry Context

The granting of stock options to directors and executives is a common practice in the biotechnology and pharmaceutical industries, serving as a standard component of compensation packages designed to attract, retain, and motivate talent by linking their financial success to the company's performance.

Comparison to Industry Standards

• The use of stock options as a form of director compensation is a widely accepted practice across the biotechnology and pharmaceutical sectors, consistent with global benchmarks for executive and board remuneration.
• The vesting schedule, requiring one year of continued service, is a typical mechanism to ensure retention and long-term commitment, comparable to similar equity grants observed at peer companies in the biopharma space.

Corporate Governance

Related Party Transactions

• The grant of stock options to Ali J. Satvat, a director of Coherus Oncology, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with shareholder value creation, potentially leading to improved long-term performance.
• Employees (including the director): The director receives a form of equity compensation that can increase their personal wealth if the company's stock price appreciates.

Next Steps

• The director's continued service with Coherus Oncology, Inc. is required for the options to vest on June 11, 2026.
• Upon vesting, the director will have the right to exercise the options to purchase common stock at the specified exercise price until the expiration date of June 12, 2035.

Key Dates

Recommendation

Keywords

Coherus Oncology, CHRS, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Beneficial Ownership, Executive Compensation